



**CLAIMS**

1. The method of using of alkylphosphocholines of the general Formula I and II:



Formula I



Formula II

in which, independently of one another,

n, m, p, z is a whole number between 0 and 4;


X is O, S, NH;

R is hydrogen, a linear or branched C<sub>1</sub> to C<sub>20</sub> alkyl group, which may be saturated or unsaturated with one to three double and/or triple bonds and unsubstituted or optionally substituted at the same or at different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C<sub>1</sub> to C<sub>6</sub> alkoxy, amino, mono-(C<sub>1</sub> to C<sub>4</sub>) alkylamino or di-(C<sub>1</sub> to C<sub>4</sub>) alkylamino groups;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> independently of one another represent hydrogen, a linear or branched (C<sub>1</sub> to C<sub>6</sub>) alkyl group, preferably methyl and ethyl, a (C<sub>3</sub> to C<sub>6</sub>) cyclo alkyl group, which may be unsubstituted or optionally substituted at the same or different carbon

atoms with one, two or more halogen, nitro, cyano, hydroxy, C<sub>1</sub> to C<sub>6</sub> alkoxy, amino, mono-(C<sub>1</sub> to C<sub>4</sub>) alkylamino or di-(C<sub>1</sub> to C<sub>4</sub>) alkylamino groups; for the manufacture of a drug product for the treatment of benign and malignant oncoses before and/or during treatment with an approved antitumor medicament; and pharmaceutically acceptable salts and prodrugs thereof.

2. The method of using of compound having the structure of Formula I:



Formula I

where, independently of one another:

n is the integer 1 or 2;

m is the integer 1;


X is O;

R is H or a straight-chain or branched (C<sub>1</sub>-C<sub>17</sub>)-alkyl group which may be saturated or unsaturated with one to three double and/or triple bonds;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> are, independently of one another, H or a straight-chain or branched (C<sub>1</sub>-C<sub>6</sub>)-alkyl group, preferably methyl and ethyl, a (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl group;

for the manufacture of a drug product for the treatment of benign and malignant oncoses before and/or during treatment with an approved antitumor medicament.

3. The method of using of alkylphosphocholines of the general Formula II as claimed in claim 1



### Formula II

where, independently of one another:

$m, p$  are the integer 1;

$n, z$  are the integer 2;

X is 0;

R is H, a straight-chain or branched (C<sub>1</sub>-C<sub>17</sub>)-alkyl group which may be saturated or unsaturated with one or two double and/or triple bonds;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> are, independently of one another, H or a straight-chain or branched (C<sub>1</sub>-C<sub>6</sub>)-alkyl group, preferably methyl and ethyl, a (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl group;

for the manufacture of a drug product for the treatment of benign and malignant oncoses before and/or during treatment with an approved antitumor medicament.

4. The method of using of octadecyl 1,1-dimethylpiperidinium-4-yl phosphate as claimed in claim 1 for the manufacture of a drug product for the treatment of benign and malignant oncoses before and/or during treatment with an approved antitumor medicament.
5. The method of using of alkylphosphocholines of the general formula I and II as claimed in claims 1 to 4, where the approved antitumor medicaments may be

alkylating agents, antimetabolites, plant alkaloids, platinum compounds, tumor antibiotics and agonists or antagonists of natural hormones.

6. The method of using as claimed in claim 5, wherein the antitumor medicaments may be cisplatin, cyclophosphamide or Adriamycin.
7. The method of using of alkylphosphocholines of the general Formula I and II as claimed in claims 1 to 4, where the approved antitumor medicaments may be inhibitors of signal transduction in the form of high and low molecular weight inhibitors of receptor and/or cytosolic kinases.
8. The method of using as claimed in claim 7, where the inhibitors may be monoclonal antibodies or heterocyclic compounds.
9. The method of using of alkylphosphocholines of the general Formula I and II as claimed in claims 1 to 8 in a therapeutic dose which is effective for the treatment before and/or during the treatment with an approved antitumor medicament.
10. The method of using of alkylphosphocholines of the general formula I and II as claimed in claims 1 to 9, where the approved antitumor medicament is a combination of various cytostatics.
11. The method of using of alkylphosphocholines of the Formula I and II as claimed in claims 1 to 4 for the manufacture of a drug product for the treatment of benign and malignant oncoses before and/or during the treatment with an approved antitumor medicament, wherein the drug product comprises the customary pharmaceutical

carriers, excipients and/or diluents in addition to the alkylphosphocholine of the Formula I and II.

12. A drug product comprising at least one alkylphosphocholine of the general Formula I and II and, where appropriate, carriers and/or excipients for use in the treatment of benign and malignant oncoses before and/or during the treatment with an approved antitumor medicament.